Drug Profile
Research programme: monoclonal antibodies - GigaGen/Trianni
Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator GigaGen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Infections
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Autoimmune-disorders in USA (Parenteral)
- 28 Sep 2021 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 28 Sep 2021 No recent reports of development identified for research development in Infections in USA (Parenteral)